January 28, 2019
Preclinical Efficiency Testing in a Rat Model of Doxorubicin-induced Cardiotoxicity Demonstrates Statistically Significant Protection
Tosk announces today that, TK-39, Tosk’s second patented product, which blocks damage to the heart resulting from a widely used class of cancer drugs known as the anthracyclines, has demonstrated preclinical efficacy testing in a well-accepted rat model. The rat model was developed by US FDA to study heart function.
The experiment examined the pumping capacity of the heart following treatment with doxorubicin. Survival also was substantially better in the animals dosed with TK-39.Tosk’s CEO, Brian Frenzel said, “This model of functional protection from doxorubicin-induced cardiotoxicity confirms previous work using biomarkers. We are ready to begin the final GLP toxicity testing needed to file an IND with the US FDA to initiate human clinical studies.”